

BAB 5

KESIMPULAN

5.1 Kesimpulan

Berdasarkan hasil penelitian yang berjudul pengaruh penggunaan metotreksat terhadap kadar BUN dan kreatinin pasien artritis rheumatoid di RSUP. Dr. Sardjito Yogyakarta diperoleh kesimpulan sebagai berikut:

Penggunaan metotreksat tidak menyebabkan peningkatan terhadap kadar BUN dan kreatinin pada pasien artritis reumatoid di RSUP. Dr. Sardjito Yogyakarta.

5.2 Saran

Berdasarkan hasil penelitian yang telah dilakukan, dapat disarankan hal sebagai berikut:

Penelitian dapat dilakukan dengan rentang waktu yang lebih lama (1 tahun) untuk mengamati pengaruh penggunaan metotreksat dalam pemakaian jangka panjang dan menilai pengaruh yang terjadi terhadap kadar BUN dan kreatinin pasien artritis reumatoid di RSUP. Dr. Sardjito Yogyakarta.

DAFTAR PUSTAKA

- Afriyanti, F.N. 2009, 'Tingkat Pengetahuan Lansia Tentang Penyakit Rheumatoid Arthritis di Panti Sosial Tresna Werdha (PSTW) Budi Mulia 1 Cipayang Jakarta Tahun 2009', *Skripsi*, Universitas Islam Negeri, Jakarta.
- Agency for Healthcare Research and Quality (AHRQ). 2008, '*Rheumatoid Arthritis Medicines A Guide for Adults*', Diakses pada 10 Oktober 2016, http://www.effectivehealthcare.ahrq.gov/repFiles/RheumArthritisConsumerGuide_Singlepage.pdf.
- Ahmed, W., Zaki, A., Nabil, T. 2015, Revention of methotrexate-induced nephrotoxicity by concomitant administration of garlic aqueous extract in rat, *Turkish Journal of Medical Sciences*. **45(3)**:507-16.
- Alamanos, Y. and Drosos, A.A. 2005, Epidemiology of Adult Rheumatoid Arthritis, *Autoimmunity Reviews*, **4(3)**:130-6.
- American College of Rheumatology. 2015, '*American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis*', Diakses pada 10 Oktober 2016, https://www.google.co.id/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=0ahUKEwiBo-bi7TQAhUYS48KHXioA6AQFgghMAA&url=http%3A%2F%2Fwww.rheumatology.org%2FPortals%2F0%2FFiles%2FACR%25202015%2520RA%2520Guideline.pdf&usq=AFQjCNEfUJP8gQow5Ag3FDDiDkBXf6nEQ&sig2=y0t_Ttorr1HGmH1JQVeEBg&cad=rja.
- Anonim, 2012, '*Patient information on methotrexate*'. Australian Rheumatology Association (ARA), Australia, pp 1.
- Anonim, 2015, '*Methotrexate*', Diakses pada 27 Januari 2018, <https://pubchem.ncbi.nlm.nih.gov/compound/methotrexate#section=Drug-and-Medication-Information>.

- Aronoff, G.R., Bennett, W.M., Morrison, G., Golper, T.A., Pulliam, J., Wolfson, M., Singer, I. 2007, *Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children*, 5thed, PA: American College of Physicians, Philadelphia.
- Arthritis Foundation, 2015, '*Arthritis Foundation Scientific Strategy 2015-2020*', Diakses pada 10 Oktober 2016, <http://www.arthritis.org/Documents/arthritis-foundationscientific-strategy.pdf>
- Badley, E, DesMeules, M. 2003. M. Introduction. In: Badley E, DesMeules M, eds. *Arthritis in Canada. An ongoing challenge*. Ottawa: Health Canada:1-6.
- Bannwarth, B., Pe´hourcq, F., Schaefferbeke, T., Dehais, J. 1996, Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis, *Clin Pharmacol*, **30**:194–210.
- Beck, O., Seideman, P., Wennberg, M. and Peterson, C. 1991, Trace analysis of methotrexate and 7-hydroxymethotrexate in human plasma and urine by a novel (HPLC) method, *Ther. Drug. Monit*, **13**: 528-532.
- Bergström, U. 2011. '*Clinical and epidemiologic aspects of Rheumatoid Arthritis*'. Special emphasis on cardiovascular outcome and risk factors Unit of Rheumatology, Dept of Clinical Sciences, Malmö.pp 21.
- Chakrabarti, S., Lekontseva, O. and Davidge, S.T. 2008, Estrogen is a modulator of vascular inflammation, *IUBMB Life*, **60**: 376–382.
- Choy, E. 2012, Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis, *Rheumatology*. doi:10.1093/rheumatology/kes113.51:v3-v11
- Costa, E., Rocha, S., Pereira, P.R., Castro, E., Reis, F., Teixeira, F., Miranda, V., Faria, M.D.S., Loureiro, A., Quintanilha, A., Belo, L. and Silva, A.S. 2008, Cross-talk Between Inflammation,

Coagulation/Fibrinolysis and Vascular Access in Hemodialysis Patients, *The Journal of Vascular Access*, **9**: 248-253.

- Cross, M., Smith, E., Hoy, D., Nolte, S., Ackerman, I., Fransen, M., Bridgett, L., Williams, S., Guillemin, F., Hill, C.L., Laslett, L.L., Jones, G., Cicuttini, F., Osborne, R., Vos, T., Buchbinder, R., Woolf A., March L.. 2014, The Global Burden of Hip and Knee Osteoarthritis: Estimates from the Global Burden of Disease 2010 Study, *Ann Rheum Dis*, **73**: 1323-1330.
- Cutolo, M., Sulli, A., Pizzorni, C., Serio, B., Straub, R.H. 2001, Antiinflammatory mechanisms of methotrexate in rheumatoid arthritis, *Ann Rheum Dis*, **60**:729-735.
- Daud, R. 2000, Tinjauan Kepustakaan: Diagnosis dan Penatalaksanaan Arthritis Reumatoid. *Cermin Dunia Kedokteran*. **129**:9.
- Furst, D.E. 1997, The rational use of methotrexate in rheumatoid arthritis and other rheumatic diseases, *Br J Rheumatol*. **36**:1196-1204.
- Gaies, E., Jebabli, N., Trabelsi, S., Salouage, I., Charfi, R., Lakhal, M., Klouz, A. 2012, Methotrexate Side Effects: Review Article, *J Drug Metab Toxicol*. **3**:125. doi:10.4172/2157-7609.1000125
- Ganong, W.F., 2001. *Buku Ajar Fisiologi Kedokteran, Ed 20th*. McGraw-Hill Companies, New York, 677, 696.
- Gilani S.T., Khan, D.A., Khan, F.A., and Ahmed, M. 2012. Adverse effects of low dose methotrexate in rheumatoid arthritis patients. *J Coll Physicians Surg Pak*, **22(2)**:101-104.
- Gordon, M.M., Hampson, R., Capell, H.A., and Madhok, R., 2002, Illiteracy in Rheumatoid Arthritis Patients as Determined by the Rapid Estimate of Adult Literacy in Medicine (REALM) Score, *British Society for Rheumatology*, **41**:750-754.
- Guyton, A.C and Hall, J.E. 2006, 'Glomerular Filtration, Renal Blood Flow, and Their Control', in Guyton, A.C and Hall, J.E., *Textbook of*

- Medical Physiology, 11thed., Elsevier Saunders Inc., Philadelphia, pp 307-311.
- Güler, N., Tander, B., Kisacik, B., Utku, U., Cevlk, A., Vehbi E., Gülçin E., Özgür E., Rahmi A., Ferhan C. 2008, Low dose methotrexate associated pancytopenia in a patient with rheumatoid arthritis, *Turk J Phys Med Rehab*, **54**: 79-81.
- Hernández, A.M, Liang, M.H., Willett, W.C., Stampfer, M.J., Colditz, G.A., Rosner, B., Roberts, W.N., Hennekens, C.H., Speizer, F.E. 1990, Reproductive factors, smoking and the risk for rheumatoid arthritis, *Epidemiology*, **1**:285–289.
- Jonsson, B. 2008, Patient access to rheumatoid arthritis treatments, *The European Journal of Health Economics*, **8 (Suppl 2)**:S35–S38.
- Kraag, G.R. 1989, Clinical Aspects in Rheumatoid Arthritis, *Triangle*, **29**: 15-24.
- Li, X., Abe, E., Yamakawa, Y., Yoneda, G., Fujino, R., Mami Y., Yuumi I., Hirofumi J., Hideyuki S. 2016, Effect of Administration Duration of Low Dose Methotrexate on Development of Acute Kidney Injury in Rats, *J Kidney*, **2**: 130.
- Longo, D.L. MD., Kasper, DL. Hauser SL, Jameson J., Loscalzo, J., Dennis L. MD., Anthony SF. MD., Eugene B. MD., 2012, ‘Rheumatoid Arthritis’, *Harrison’s Principle of Internal Medicine*, 8th ed., McGraw-Hill Companies, Inc., USA.
- Mäkinen, Heidi. 2008. Disease Activity and Remission in Rheumatoid Arthritis. *Comparision of Available Disease Activity Measures and Development of a Novel Disease Activity Index- the Mean Overall Index for Rheumatoid Arthritis (MOI-RA)*. Kuopio University.
- Mancintyre, P. E., and Schug, S.A. 2007, *Acute Pain Management A Partical Guide*, 3rd ed. Saunders Elsevier, China, Page: 216-220.

- Marieb, Elaine, N., and Hoehn, K. 2010, *Human Anatomy & Physiology*, 8thed. Benjamin Cummings, USA.
- McPhee, S.J. and Ganong, W.F. 2006, 'Renal Disease' in McPhee, S.J and Ganong, W.F., *Pathophysiology of Disease: An Introduction to Clinical Medicine*, 5th ed., Mc Graw Hill Companies Inc., New York
- Mota, L.M., Brenol, C.V., Palominos, P., Pinheiro, Gda.R.. 2015, Rheumatoid arthritis in Latin America: the importance of an early diagnosis. *Clin Rheumatol*, **34**(1): 29–44.
- Muchid, A. 2006. *Pharmaceutical Care untuk Pasien Penyakit Arthritis Rematik*. Direktorat Bina Farmasi Komunitas dan Klinik, Ditjen Bina Kefarmasian dan Alat Kesehatan, Jakarta.hal 1.
- Nainggolan, O. 2009, Prevalensi dan Determinan Penyakit Rheumatik di Indonesia. *Majalah Kedokteran Indonesia*, **59**: 587-594.
- Nasution, A.R dan Sumarlyono. 2009, *Introduksi Reumatologi Dalam :Buku Ajar Ilmu Penyakit Dalam*. Jakarta: Fakultas Kedokteran Universitas Indonesia. **V**: 2353-9
- NCCCC - National Collaborating Centre for Chronic Conditions. 2009. 'Rheumatoid arthritis: national clinical guideline for management and treatment in adults' Royal College of Physicians: London.
- Pagana, K.D and Pagana, T.J. 2002, *Manual of Diagnostic and Laboratory Test*, Mosby Inc., Missouri.
- Pearce. 1995, *Anatomi dan Fisiologi untuk Paramedis*, PT Gramedia Pustaka Utama, Jakarta.
- Perhimpunan Reumatologi Indonesia. 2014. Rekomendasi Perhimpunan Reumatologi Indonesia Untuk Diagnosis dan Pengelolaan Arthritis Reumatoid: Perhimpunan Reumatologi Indonesia.

- Price, SA, Wilson, LM. 2005. *Patofisiologi : Konsep Klinis Proses-Proses Penyakit*. Volume 2 Ed/6. Hartanto H, Susi N, Wulansari P, Mahanani DA, editor. Jakarta: EGC, hal. 1385-1391
- Pollard, L., Choy, E.H., and Scott, D.L. 2005, The Consequences of Rheumatoid Arthritis: Quality of Life Measures in The Individual Patient, *Clinical Experimental Rheumatology*, **23**:S43-S52.
- Rachel, A. Burke & Nicole D. White. 2014. *Biologic Disease-Modifying Antirheumatic Drugs*. PSAP: Chronic Illnesses II.
- Schneider, Matthias, Krüger, and Klaus. 2013, *Rheumatoid Arthritis—Early Diagnosis and Disease Management*. Deutsches Ärzteblatt International. Jerman.
- Schuna, A.A., Dipiro, J.T., Talbert, R.L., Yee, G.C. Matzke, G.R., Wells, B.G. & Posey, L.M., (Eds), 2008, 'Rheumatoid Arthritis' in Schuna, A.A., Dipiro, J.T., Talbert, R.L., Yee, G.C. Matzke, G.R., Wells, B.G. & Posey, L.M., (Eds), *Pharmacotherapy A Pathophysiologic Approach, 7th Edition*, McGraw Hill, Medical Publishing Division, New York, 1505-1515.
- Silman, A.J. 2002, The Changing Face of Rheumatoid Arthritis: Why the Decline in Incidence? *Arthritis & Rheumatism*, **46(3)**: 579-581.
- Smolen, J.S., Landewé, R., Breedveld, F.C., Buch, T, Burmester, G.R., Dougados, M. 2014, EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update, *Ann Rheum Dis*, **73(3)**:492–509.
- Statistics Netherlands. 2010, CBS StatLine: Reported health and lifestyle. Diakses pada 1 November 2016, <http://statline.cbs.nl/StatWeb/selection/?DM=SLLEN&PA=03799ENG&LA=EN&VW=T>.

- Suarjana, I.N. 2009. *Artritis Reumatoid Dalam Buku Ajar Ilmu Penyakit Dalam* Edisi V. Sudoyo, A.W., Setiyohadi, B., Alwi, I., Simadibrata, M., Setiati, S. Interna Publishing. Jakarta.
- Symmons D.P. 2005. 'Looking back: rheumatoid arthritis--aetiology, occurrence and mortality'. *Rheumatology* (Oxford). **Suppl 4**:iv14-iv17.
- Tanner, G.A. 2013. *Medical Physiology: Renal physiology and Body Fluids*. Philadelphia. Wolters Kluwer Health/Lippincott Williams & Wilkins. Chapter-22 Kidney Function; pp-393
- Tian, H. and Cronstein, B. N. 2007, Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. *Bulletin of the NYU Hospital for Joint Diseases*, **65(3)**:168-73.
- Verdiansah. 2016. Pemeriksaan Fungsi Ginjal. Program Pendidikan Dokter Spesialis Patologi Klinik Rumah Sakit Hasan Sadikin. Bandung. *Cermin Dunia Kedokteran*. **43(2)**: 148-154.
- Widemann B.C. and Adamson, P.C. 2006, Understanding and managing methotrexate nephrotoxicity, *The Oncologist*, **11**:694-703.
- Williams, Lippincott & Wilkins. 2011, *Professional Guide to Pathophysiology*, 3rd Ed, Wolters Kluwer Health, Norristown, 435-458.
- Wilson, L.M. and Price, S.A. 1995, *Patofisiologi: Konsep Klinis Proses-Proses Penyakit*, Penerbit Buku Kedokteran EGC, Jakarta.
- Zhang, S.X., Miao M., Liu, X.Q., Ma, X.W., Wu, X.Y., Li, X.F. 2016, The Efficacy and Safety of Low Dose IL-2 Therapy in over-Treated Patients with Rheumatoid Arthritis: A Preliminary Study [abstract], *Arthritis Rheumatol*, **68 (10)**: 4-2.